SANTA CLARA, Calif., Sept. 9 /PRNewswire-FirstCall/ -- NewCardio, Inc., a cardiac diagnostic and services company, today announced that a Top Five Clinical Research Organization (CRO), which is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has signed a Master Services Agreement (MSA) with NewCardio. Under the terms of this agreement, the CRO will receive a license to use NewCardio’s QTinno(TM) software solution in all TQT studies where fully automated readings are obtained.
“The adoption of QTinno(TM) by the clinical pharmacology units at this top five CRO will enable them to deliver quality TQT/QT studies with higher accuracy and lower intrinsic variability in a timely and cost-effective manner,” said Vincent Renz, NewCardio’s President and Chief Operating Officer. “The ability to extend the scope of services provided through its three clinical pharmacology units in the delivery of TQT/QT studies, effectively as a one-stop-shop provider, provides a powerful competitive advantage further differentiating itself from its competitors.”
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio’s development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio’s three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
SOURCE NewCardio, Inc.
CONTACT: Jeff Stanlis, Partner and VP of Communications, Hayden IR,
+1-602-476-1821, jeff@haydenir.com
Web site: http://www.newcardio.com/
